Arcus Biosciences Inc [RCUS] stock is trading at $23.09, down -0.13%. An important factor to consider is whether the stock is rising or falling in short-term value. The RCUS shares have gain 5.00% over the last week, with a monthly amount drifted -4.90%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcus Biosciences Inc [NYSE: RCUS] stock has seen the most recent analyst activity on February 26, 2025, when H.C. Wainwright upgraded its rating to a Buy and also boosted its price target to $24 from $18. Previously, H.C. Wainwright started tracking the stock with Neutral rating on October 21, 2024, and set its price target to $20. On October 08, 2024, Wells Fargo initiated with an Overweight rating and assigned a price target of $29 on the stock. BofA Securities started tracking the stock assigning a Neutral rating and suggested a price target of $33 on November 18, 2022. Morgan Stanley initiated its recommendation with an Overweight and recommended $40 as its price target on October 11, 2022. In a note dated November 24, 2020, Berenberg initiated a Buy rating and provided a target price of $50 on this stock.
Arcus Biosciences Inc [RCUS] stock has fluctuated between $6.50 and $26.40 over the past year. Currently, Wall Street analysts expect the stock to reach $28.25 within the next 12 months. Arcus Biosciences Inc [NYSE: RCUS] shares were valued at $23.09 at the most recent close of the market. An investor can expect a potential return of 22.35% based on the average RCUS price forecast.
Analyzing the RCUS fundamentals
Arcus Biosciences Inc [NYSE:RCUS] reported sales of 240.00M for the trailing twelve months, which represents a drop of -45.83%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -1.56%, Pretax Profit Margin comes in at -1.45%, and Net Profit Margin reading is -1.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.7 and Total Capital is -0.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.72 points at the first support level, and at 22.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.38, and for the 2nd resistance point, it is at 23.68.
Ratios To Look Out For
For context, Arcus Biosciences Inc’s Current Ratio is 3.65. On the other hand, the Quick Ratio is 3.65, and the Cash Ratio is 1.01. Considering the valuation of this stock, the price to sales ratio is 11.90, the price to book ratio is 5.67.
Transactions by insiders
Recent insider trading involved Tang Carolyn C., General Counsel, that happened on Dec 16 ’25 when 7658.0 shares were sold. General Counsel, Tang Carolyn C. completed a deal on Dec 17 ’25 to sell 6810.0 shares. Meanwhile, Chief Medical Officer Markus Richard sold 5052.0 shares on Dec 16 ’25.
